Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

Pantethine is effective and well tolerated for treatment of dyslipidemia, study shows

Highlights

  • Systematic review of 28 clinical trials (646 hyperlipidemic subjects)
  • Median pantethine dosage is 900 mg/day (300 mg, three times daily)
  • Significant improvement in total and LDL cholesterol and triglycerides
  • Treatment well tolerated (AER) 1.4 per 100 subjects), mostly mild GI complaints

Summary

This systematic review of 28 clinical trials with a total of 646 hyperlipidemic subjects indicates pantethine is effective and well tolerated for the treatment of high blood lipids. The average study included 22 subjects, average age 53 years, and lasted 13 weeks. The median dosage of pantethine was 900 mg/day with a range of 600 to 1,200 mg/day. The most common dosage was 300 mg, three times daily. Results indicate that, by month 4, all parameters except HDL cholesterol were significantly improved (see Table 1).

Treatment was well tolerated with an adverse event rate (AER) of 1.4 per 100 subjects, mostly mild gastrointestinal (GI) complaints.

These findings suggests that pantethine offers an effective, well-tolerated therapeutic option for treating patients with total cholesterol levels greater than 200 mg/dL and/or triglyceride levels greater than 150 mg/dL.

 

Table 1. Average Change in Blood Lipids (Baseline to Month 4)

Parameter

Month 1

Month 2

Month 3

Month 4

Total Cholesterol

-8.7%

-11.6%

-12.6%

-15.1%

LDL Cholesterol

-10.4%

-15.2%

-17.7%

-20.1%

HDL Cholesterol

+6.1%

+7.8%

+10.7%

+8.4%*

Triglycerides

-14.2%

-15.8%

-23.7%

-32.9%

*Not a significant change.
Source: McRae MP. Nutr Res. 2005;25:319-333.

Reference

McRae MP. Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability. Nutr Res. 2005;25:319-333.